Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.

Article  PubMed  PubMed Central  Google Scholar 

Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5(1):37–50.

Article  CAS  PubMed  Google Scholar 

Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014;8(3):798–806.

Article  CAS  PubMed  Google Scholar 

De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21(5):655–67.

Article  PubMed  PubMed Central  Google Scholar 

Chen YC, Gotea V, Margolin G, Elnitski L. Significant associations between driver gene mutations and DNA methylation alterations across many cancer types. PLoS Comput Biol. 2017;13(11):e1005840.

Article  PubMed  PubMed Central  Google Scholar 

Youn A, Kim KI, Rabadan R, Tycko B, Shen Y, Wang S. A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes. BMC Med Genomics. 2018;11(1):98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE. 2011;6(3):e17388.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2’-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58(1):95–101.

CAS  PubMed  Google Scholar 

Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, et al. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014;6(1):13.

Article  PubMed  PubMed Central  Google Scholar 

Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn WC, et al. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther. 2011;10(9):1611–23.

Article  CAS  PubMed  Google Scholar 

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5(3):587–98.

Article  PubMed  PubMed Central  Google Scholar 

Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248.

Article  PubMed  PubMed Central  Google Scholar 

Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment. Int J Cancer. 2001;94(2):243–51.

Article  CAS  PubMed  Google Scholar 

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an Interferon Response in Cancer via dsRNA. Including Endogenous Retroviruses Cell. 2017;169(2):361.

CAS  PubMed  Google Scholar 

Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating agents Target Colorectal Cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gjerstorff MF, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opin Biol Ther. 2010;10(7):1061–75.

Article  CAS  PubMed  Google Scholar 

Traynor S, Terp MG, Nielsen AY, Guldberg P, Jakobsen M, Pedersen PG, et al. DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1. Cancer Lett. 2023;552:215982.

Article  CAS  PubMed  Google Scholar 

Gjerstorff MF. Epigenetic targeting of myeloid-derived suppressor cells: time to move into infectious diseases? Front Immunol. 2023;14:1247715.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6(18):15772–87.

Article  PubMed  PubMed Central  Google Scholar 

Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–25.

Article  CAS  PubMed  Google Scholar 

Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8 + progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023;133(7).

Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111(32):11774–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2014;20(24):6504–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, et al. Low dose Decitabine Combined with Taxol and Platinum Chemotherapy to treat Refractory/Recurrent ovarian Cancer: an Open-Label, Single-Arm, phase I/II study. Curr Protein Pept Sci. 2015;16(4):329–36.

Article  CAS  PubMed  Google Scholar 

Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO. Epigenetic reactivation of estrogen receptor-alpha (ERalpha) by genistein enhances hormonal therapy sensitivity in ERalpha-negative breast cancer. Mol Cancer. 2013;12:9.

Article  PubMed  PubMed Central  Google Scholar 

Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008;134(8):883–90.

Article  CAS  PubMed  Google Scholar 

Wu M, Sheng L, Cheng M, Zhang H, Jiang Y, Lin S, et al. Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene. 2019;38(27):5425–39.

Article  CAS  PubMed  Google Scholar 

Wang C, Liu Y, Dong L, Li X, Yang Q, Brock MV, et al. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in patients with Hodgkin Lymphoma who progressed or relapsed after PD-1 Blockade Monotherapy. Clin Cancer Res. 2021;27(10):2782–91.

Article  CAS  PubMed  Google Scholar 

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to Anti-PD-1 antibody camrelizumab in Relapsed/Refractory classical Hodgkin Lymphoma. J Clin Oncol. 2019;37(17):1479–89.

Article  CAS  PubMed